Endologix LLC Receives FDA Breakthrough Device Designation for ChEVAS™ System

The FDA Breakthrough Devices Program gives patients more timely access to medical devices that may provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. Breakthrough Devices receive priority review by FDA, and the program provides opportunities for early interaction with FDA personnel to expedite the review and approval process.

ChEVAS is currently being evaluated through the ChEVAS ONE IDE (Investigational Device Exemption) clinical study that is approved to enroll approximately 120 patients at up to 50 clinical sites worldwide. The national principal investigators of the ChEVAS ONE study are Francis Caputo, MD (Cleveland Clinic Foundation); William Jordan, MD (Emory University School of Medicine); Joseph Lombardi, MD (Cooper University Health Care) and William Quinones-Baldrich, MD (UCLA).

“The aneurysm sac sealing technology featured in the ChEVAS system is designed to reduce endoleaks, including gutter endoleaks, that are reported after endovascular treatment of complex aneurysms,” said James McKinsey, MD, the leading enroller in the ChEVAS ONE IDE study. “Our initial clinical results of this therapy have been promising in a challenging group of patients.”

Dr. McKinsey will present his initial experience with ChEVAS at the Eastern Vascular Society Annual Meeting on Sept. 26.

“The ChEVAS System represents an important therapy that provides an ‘off-the shelf’ treatment to an underserved patient population who have complex abdominal aortic aneurysms,” said Matt Thompson, MD, chief medical officer at Endologix. “We are delighted that the FDA has designated ChEVAS as a Breakthrough Device, as this will facilitate our ability to develop this technology and make it available to patients in an expedited fashion. The ChEVAS System joins the PQ Bypass DETOUR System as the two FDA designated Breakthrough Devices in our clinical investigational programs, which is reflective of our aspiration to provide innovative and disruptive technologies to address clinically relevant therapeutic gaps.”

About Endologix
Endologix LLC is a California-based, global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease. Endologix’s therapeutic portfolio includes a variety of products in various stages of development that are designed to treat diseases that currently have clinically relevant unmet needs. These products are meant to treat a wide spectrum of vascular disease from abdominal aortic aneurysms to lower limb peripheral vascular disease. Excellent clinical outcomes will be achieved through meticulous attention to product design, manufacturing, and training, all backed by industry-leading clinical evidence. Endologix’s abdominal aortic aneurysm (AAA) products are built on one of two platforms: Traditional minimally invasive endovascular aneurysm repair (“EVAR”) and endovascular aneurysm sealing (“EVAS”), which is investigational product. Endologix’s current commercial EVAR products include the AFX^®2 device and the ALTO^® Abdominal Stent Graft System. Endologix became a private company, wholly owned by Deerfield Management on Oct. 1, 2020. The company has offices and manufacturing sites in Irvine and Santa Rosa. To learn more about Endologix, please visit http://www.endologix.com/.

About Deerfield Management
Deerfield is an investment management firm committed to advancing healthcare through investment, information, and philanthropy. For more information, please visit www.deerfield.com.

Cautions Regarding Forward-Looking Statements
Except for historical information contained herein, this press release contains forward-looking statements, including statements regarding future clinical trials. Forward-looking statements are subject to risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. The forward-looking statements contained in this press release speak only as of the date of this press release and Endologix undertakes no obligation to update any forward-looking statements contained in this press release to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.